Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-11-30, Stock:LLY, The news for the past five days is as follows:
2018-11-23: NEWS1: See what the IHS Markit Score report has to say about Eli Lilly and Co..
2018-11-26: NEWS1: Jardiance® Recommended as Preferred SGLT2 Inhibitor for Adults with Type 2 Diabetes and Established Cardiovascular Disease in American College of Cardiology Expert Consensus Decision Pathway.NEWS2: 4 Reasons Why Lilly is Up More Than 30% This Year So Far.NEWS3: 4 Reasons Why Lilly is Up More Than 30% This Year So Far.NEWS4: 4 Reasons Why Lilly is Up More Than 30% This Year So Far.
2018-11-27: NEWS1: Zafgen (ZFGN) Plunges as FDA Puts Hold on Diabetes Drug Trial.NEWS2: Lilly to Announce 2019 Financial Guidance, Highlight Late-Stage Pipeline Opportunities and Discuss Commercial Performance at Upcoming Investment Community Meeting.NEWS3: American College of Cardiology recommends empagliflozin as preferred SGLT2 inhibitor for adults with type 2 diabetes and established cardiovascular disease in new Expert Consensus Decision Pathway.
2018-11-28: NEWS1: Is Eli Lilly and (LLY) Stock Outpacing Its Medical Peers This Year?.NEWS2: Is Eli Lilly and (LLY) Stock Outpacing Its Medical Peers This Year?.NEWS3: Is Eli Lilly and (LLY) Stock Outpacing Its Medical Peers This Year?.NEWS4: Zafgen (ZFGN) Plunges as FDA Puts Hold on Diabetes Drug Trial.NEWS5: Zafgen (ZFGN) Plunges as FDA Puts Hold on Diabetes Drug Trial.
2018-11-29: NEWS1: Merck (MRK) Receives Approval for 2 HIV Medicines in EU.NEWS2: Merck (MRK) Receives Approval for 2 HIV Medicines in EU.NEWS3: Merck (MRK) Receives Approval for 2 HIV Medicines in EU.NEWS4: iShares Edge MSCI Min Vol Global ETF Experiences Big Inflow.NEWS5: iShares Edge MSCI Min Vol Global ETF Experiences Big Inflow.NEWS6: Alkermes touts &apos;positive&apos; schizophrenia drug data, but investors not impressed.NEWS7: Alkermes shares dip despite &apos;positive&apos; trial results from schizophrenia drug.NEWS8: 4 Big Pharma Stocks to Add to Your Portfolio in December.NEWS9: 4 Big Pharma Stocks to Add to Your Portfolio in December.NEWS10: 4 Big Pharma Stocks to Add to Your Portfolio in December.NEWS11: Lilly to Present Clinical Data for Verzenio® (abemaciclib) and Real-World Evidence across HR+, HER2- Metastatic Breast Cancer at 2018 SABCS.

Answer: Rise